Last reviewed · How we verify

Rivaroxaban granules for oral suspension

Bayer · Phase 2 active Small molecule

Rivaroxaban granules for oral suspension is a Small molecule drug developed by Bayer. It is currently in Phase 2 development. Also known as: Xarelto, BAY59-7939.

At a glance

Generic nameRivaroxaban granules for oral suspension
Also known asXarelto, BAY59-7939
SponsorBayer
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rivaroxaban granules for oral suspension

What is Rivaroxaban granules for oral suspension?

Rivaroxaban granules for oral suspension is a Small molecule drug developed by Bayer.

Who makes Rivaroxaban granules for oral suspension?

Rivaroxaban granules for oral suspension is developed by Bayer (see full Bayer pipeline at /company/bayer).

Is Rivaroxaban granules for oral suspension also known as anything else?

Rivaroxaban granules for oral suspension is also known as Xarelto, BAY59-7939.

What development phase is Rivaroxaban granules for oral suspension in?

Rivaroxaban granules for oral suspension is in Phase 2.

Related